Bhat Amoolya, Chowdappa Vijaya, Masamatti Smita Surendra
Assistant Professor, Department of Pathology, Sapthagiri Institute of Medical Sciences and Research Centre , Bengaluru, Karnataka, india .
Professor and Head, Department of Pathology, Sapthagiri Institute of Medical Sciences and Research Centre , Bengaluru, Karnataka, india .
J Clin Diagn Res. 2016 Jul;10(7):EC21-4. doi: 10.7860/JCDR/2016/19278.8213. Epub 2016 Jul 1.
Dengue affects more than 50 million people per year and is one of the most common causes of severe thrombocytopaenia. Thrombocytopaenia is a common complication of dengue and other viral fevers apart from malaria, typhoid, leptospirosis, leukaemia and megaloblastic anaemia. A platelet count of <20,000/μl is characteristically seen in dengue haemorrhagic fever and dengue fever. It results from immune complex mediated platelet destruction or bone marrow suppression. Severe thrombocytopaenia <10,000/μl is one of the indications for prophylactic platelet transfusion therapy to prevent haemorrhage.
To evaluate the effectiveness of transfusion of ABO compatible and ABO incompatible pooled platelet units in severe thrombocytopaenia cases.
In this study ABO compatible and incompatible pooled platelet units were transfused to serologically confirmed dengue cases having thrombocytopaenia with or without bleeding manifestations. Each of the adult patients received 4-6 units of pooled platelet concentrates prepared from random donor whole blood suspended in plasma for severe thrombocytopaenia. Pre and post transfusion platelet counts were compared. Children aged less than 12 years, pregnant women and patients with splenomegaly those on ayurvedic and homeopathic therapy, recipients of packed red cells on the same day of platelet transfusion and recipients of multiple platelet transfusions within 24 hours were excluded from the study.
The median post transfusion platelet increments (PPI) and corrected count increments (CCI) at 4hour post transfusion were 25,000/μL (5,000-80,000/μL) and 18,000/μL (range 8,000/μL- 47,500/μL) respectively among the responders. Median PPI and CCI at 24 hours were 45,000/μL and 28,863/μL among the responders. The median CCI at 4 hour post transfusion among the non-responders was 850/μL and at 24hours was 1,425/μL. At 24 hours responders showed significantly higher PPI as compared to non responders. The average platelets transfused were 4units in case of responders and 8 units in case of non-responders.
ABO identical and compatible pooled platelet transfusions were more successful in increasing the post transfusion platelet counts as compared to ABO incompatible pooled platelets.
登革热每年影响超过5000万人,是严重血小板减少症最常见的病因之一。血小板减少症是登革热以及除疟疾、伤寒、钩端螺旋体病、白血病和巨幼细胞贫血之外的其他病毒热的常见并发症。登革出血热和登革热患者的血小板计数特征性地低于20,000/μl。这是由免疫复合物介导的血小板破坏或骨髓抑制导致的。严重血小板减少症(<10,000/μl)是预防性血小板输注治疗以预防出血的指征之一。
评估输注ABO相容和ABO不相容混合血小板单位对严重血小板减少症病例的有效性。
在本研究中,将ABO相容和不相容的混合血小板单位输注给血清学确诊的患有血小板减少症且有或无出血表现的登革热病例。每位成年患者接受4 - 6单位由随机供体全血制备的混合血小板浓缩物,这些全血悬浮于血浆中用于治疗严重血小板减少症。比较输血前后的血小板计数。年龄小于12岁的儿童、孕妇、脾肿大患者、接受阿育吠陀和顺势疗法治疗的患者、在血小板输注当天接受红细胞输注的患者以及在24小时内接受多次血小板输注的患者被排除在研究之外。
在有反应者中,输血后4小时的血小板增加值(PPI)中位数和校正计数增加值(CCI)分别为25,000/μL(5,000 - 80,000/μL)和18,000/μL(范围8,000/μL - 47,500/μL)。有反应者在24小时时的PPI和CCI中位数分别为45,000/μL和28,863/μL。无反应者在输血后4小时的CCI中位数为850/μL,24小时时为1,425/μL。在24小时时,有反应者的PPI显著高于无反应者。有反应者平均输注血小板4单位,无反应者平均输注8单位。
与ABO不相容的混合血小板相比,ABO相同和相容的混合血小板输注在增加输血后血小板计数方面更成功。